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The incidence of the species Candida albicans and non-albicans Candida was evaluated in a
Brazilian Tertiary Hospital from the environment and health practitioners. In a 12-month
period we had a total positivity of 19.65% of Candida spp. The most recurring non-albicans
Candida species was C. glabrata (37.62%), generally considered a species of low virulence, but
with a higher mortality rate than C. albicans. Subsequently, C. parapsilosis (25.74%) and C.
tropicalis (16.86%) were the second and third most commonly isolated species. Considering
the  total samples collected from the emergency room and from the inpatient and the pedi-
atric sector, 19.10% were positive for Candida spp., with the predominance of non-albicans
Candida species (89.42%). The high percentage of positivity occurred in the hands (24.32%)
and  the lab coats (21.88%) of the health care assistants. No sample of C. albicans presented a
proﬁle of resistance to the drugs. All the non-albicans Candida species presented a decreased
susceptibility to miconazole and itraconazole, but they were susceptible to nystatin. Most
of  the isolates were susceptible to ﬂuconazole and amphotericin B. As expected, a high
resistance rate was observed in C. glabrata and C. krusei, which are intrinsically less suscep-
tible to this antifungal agent. The contamination of environmental surfaces by Candida spp.
through hand touching may facilitate the occurrence of Candida infections predominantly
in  immunocompromised patients. In addition to that, the antifungal agents used should
be  carefully evaluated considering local epidemiologic trends in Candida spp. infections, so
that  therapeutic choices may be better guided.©  2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Microbiologia. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
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ttp://dx.doi.org/10.1016/j.bjm.2015.05.001
517-8382/© 2016 Published by Elsevier Editora Ltda. on behalf of Soci
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/edade Brasileira de Microbiologia. This is an open access article
by-nc-nd/4.0/).
 i c r o368  b r a z i l i a n j o u r n a l o f m
Introduction
The frequency of Candida spp. hospital infections has
increased worldwide in recent years and it has been accom-
panied by a signiﬁcant rise in morbidity and mortality. An
important issue of public health involves the long time hospi-
tal stay due to the difﬁculty in the diagnosis, prevention, and
treatment of invasive fungal infections.1,2
Candida spp. may cause serious nosocomial infections and
it represents the fourth most frequent agent isolated from
bloodstream infections in many  regions. Candida albicans is
the main species that causes hospital-acquired infections,
although other species of non-albicans Candida, such as C. trop-
icalis, C. parapsilosis, C. glabrata, C. krusei and C. lusitaniae have
shown an increased incidence of nosocomial infections.3,4
While C. albicans remains the most common Candida species
in infections, C. glabrata, generally considered a species of low
virulence but with a higher mortality rate than C. albicans, has
represented approximately 15–20% of all Candida infections in
the United States and has been considered the most common
non-albicans Candida isolated species.5
The hospital environment is inevitably a large reser-
voir of opportunistic pathogens, which may be transmitted
to individuals in different ways. The modes of transmis-
sion and input port to hospital-acquired fungal infections
vary according to the pathogen involved. Candida spp. infec-
tions are predominantly of an endogenous origin, but the
cross-infection transmitted through the hands of health care
practitioners or relatives, or even through hospital devices, has
occurred constantly.6 Furthermore, it is known that antifungal
resistance is an important concern related to almost all main
groups of pathogenic microorganisms, including the Candida
species. The increasing use of prophylactic ﬂuconazole in
high-risk patients has played an important role in decreasing
the incidence of C. albicans infections without affecting the
incidence of infections caused by non-albicans Candida species,
such as C. glabrata and C. krusei.7
An inappropriate antifungal therapy and the occurrence of
resistant species may have an impact on the mortality rates. A
correlation between reduced antifungal susceptibility in non-
albicans Candida species and the use of antifungal prophylaxis
have been suggested. Data about patterns of resistance of
etiological agents are powerful tools to guide a prophylactic,
preemptive, and empiric antifungal therapy.4,8
The aim of this study was to evaluate the incidence of C.
albicans and non-albicans Candida isolated from the environ-
ment and from health practitioners to identify the hospital
reservoirs of Candida spp. in a Brazilian tertiary-care hospital
and to evaluate the susceptibility of the isolated samples to
antifungal agents.
Materials  and  methods
IsolatesSamples from the environment and from health care practi-
tioners were compiled throughout a 1-year period (2008–2009),
from a tertiary care center with 140 beds that provides general b i o l o g y 4 7 (2 0 1 6) 367–372
and specialized assistance as well as surgical and intensive
care. After the isolation, the pure cultures were stored at
−20 ◦C in 15% glycerol.
Sample  collection
The samples were collected from three different sources in
the hospital environment: surfaces of hospital departments
(including emergency room, inpatient sector, and pediatric
sector), hands and lab coats of health care practitioners,
totaling 445, 37 and 32 samples in each source respectively.
Samples were collected with sterile swabs soaked in physi-
ological solution supplemented with 0.5 g/l chloramphenicol
and placed in brain-heart infusion (BHI) broth supplemented
with 0.5 g/l chloramphenicol. Samples from the lab coats of
health care professionals were collected by pressing a Petri
dish, measuring 4 cm in diameter and containing BHI agar sup-
plemented with 0.5 g/l chloramphenicol, on the frontal part of
the lab coats, about 5 cm proximal to the pockets. All plates
were incubated at 35 ◦C for 48 h.
Sample  identiﬁcation
An analysis of the growth in a chromogenic culture medium
(CHROMagar Candida®) facilitated the determination of purity
of colonies and the identiﬁcation of Candida spp. Macromor-
phological/micromorphological analysis and physiological
tests such as zymograms  and auxanograms were performed
to conﬁrm the results of the chromogenic culture medium.9,10
Determination  of  the  pattern  of  response  to  antifungal
drugs
30 samples of Candida spp. were pre-selected according to their
best growth pattern and thereby antifungal tests were con-
ducted with these 30 pre-selected samples of Candida spp.
through disk diffusion methodology and the results were
interpreted as susceptible (S), susceptible dose-dependent
(SDD), or resistant (R), based on documents M44-A2.11 The
susceptibility proﬁle of Candida spp. was analyzed with the
antifungal drugs ﬂuconazole (25 g disk), amphotericin B
(100 g disk), nystatin (100 IU disk), itraconazole (10 g disk),
miconazole, and ketoconazole (50 g discs). C. krusei (ATCC
6258) and C. parapsilosis (ATCC 22019) were used as test con-
trols. The evaluation of response proﬁles of Candida spp. to
different antifungal agents was performed in triplicate and
on different days.
Statistical  analysis
The Chi-square test or the statistic of Fisher was applied
to evaluate the signiﬁcance of differences in the frequency
distribution of the isolates. Differences with p < 0.05 were con-
sidered signiﬁcant.Results
514 samples were collected from the hospital environment
and from health care practitioners, of which 445 were
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Table 1 – Incidence of Candida species among isolates from the environment and the staff of a Brazilian tertiary hospital.
Candida species
n (%)
Collection  sites
Hospital departments Hands Lab coats Total
C. glabrata 30  (35.29) 4  (44.44) 4 (57.14) 38 (37.62)
C. parapsilosis 22  (25.99) 3  (33.33) 1 (14.28) 26 (25.74)
C. tropicalis 16 (18.82) 1 (11.11) – 17 (16.83)
C. albicans 9 (10.58) – 1 (14.28) 10 (9.90)
C. krusei 6 (7.05) 1 (11.11) – 7 (6.93)
C. lusitaniae 1 (1.17) – 1 (14.28) 2 (1.98)
C. famata 1 (1.17) – – 1 (0.99)
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ollected from surfaces, 37 from hands, and 32 from lab coats.
mong the collected samples, 101 samples (19.65%) were pos-
tive for Candida spp. Only 10 (9.90%) were identiﬁed as C.
lbicans and 91 (90.10%) were grouped as non-albicans Can-
ida. The difference of distribution was considered highly
igniﬁcant (p < 0.0001) (Table 1). The positivity according
o the collection sites was 19.10% of surfaces of hospi-
al departments, 24.32% of hands, and 21.88% of lab coats
f health care practitioners. Thus, the prevalence of Can-
ida spp. was not signiﬁcantly different (p > 0.05) among
ollection sites. The frequency distribution of the isolates
ccording to the species shows a highly signiﬁcant difference
p < 0.0001). C. glabrata was the predominant species (37.62%),
ollowed by C. parapsilosis (25.74%), C. tropicalis (16.83%), C.
lbicans (9.90%), C. krusei (6.93%), C. lusitaniae (1.98%) and C.
amata (0.99%) (Table 1). Among the isolates obtained from
ands, no isolate of C. albicans was found and the most
requent species was C. glabrata (44.44%). A prevalence of
on-albicans Candida species was also observed in isolates
rom lab coats of health care practitioners and surfaces of
ospital departments, being C. glabrata the most frequent
pecies with 57.14% and 37.62%, respectively. However, the
requency in the distribution of the isolates of C. glabrata
mong the collection sites showed no signiﬁcant difference
p = 0.4808).
usceptibility  tests
ll the samples were susceptible to nystatin and most Can-
ida isolates were susceptible to ﬂuconazole, with exception
f isolates of C. krusei and C. glabrata that are intrinsically
ess susceptible to this antifungal agent. All isolates of C.
rusei were classiﬁed as resistant to ﬂuconazole (Table 2).
n relation to amphotericin B the isolates of C. albicans and
on-albicans Candida were susceptible, except one isolate of
. krusei that presented intermediate susceptibility. No sam-
le of C. albicans presented resistance to evaluated drugs. All
solates of C. albicans were susceptible to amphotericin B, keto-
onazole and nystatin, but in relation to itraconazole, most
f them were intermediate. All the non-albicans Candida iso-
ates presented some resistance or decreased susceptibility to
iconazole and itraconazole, but all of them were susceptible
o nystatin (Table 2).Discussion
Hospital-acquired infections caused by yeasts represent a per-
sistent public health problem and a frequent complication
among patients admitted to the hospital. Candida spp. has
been the most frequently isolated agent, which corresponds to
approximately 80% of the hospital-acquired fungal infections
that cause death to 12% to 60% of the patients who  develop
candidemia.5
We  had a positivity of 19.65% for Candida spp. among the
samples isolated from the emergency room and from the inpa-
tient and pediatric sectors, hands and lab coats of health care
practitioners during the 12-month period of collection and
our results were similar to those obtained by Storti et al.,12
which found a positivity of 19.20%. The non-albicans Candida
species were predominant (90.10%) and were represented by
C. glabrata, C. parapsilosis, C. tropicalis, C. krusei,  C. lusitaniae and
C. famata.
In the research, a high rate of non-albicans Candida was
found among the health care practitioners including hands
and lab coats (85.72%) and all the isolates of Candida spp.
from the hands were non-albicans Candida. Among the results
obtained by Storti et al.,12 only one isolate of hands of a health
care assistant was of C. albicans and the incidence of Candida
spp. found among the practitioners was 15.7%, a lower aver-
age than those previously veriﬁed by other studies including
ours. Our results disagree with those obtained by Martins-
Diniz et al.,13 in which 23% of positive samples obtained from
staff members correspond to C. albicans and 19% correspond
to other species. In the work cited, 66 positive samples of yeast
were isolated, and 46 of these samples were positive for Can-
dida spp.
The predominance of non-albicans Candida species (89.42%)
was observed among the positive samples for Candida spp.
from the surfaces of hospital departments with prevalence of
C. glabrata (37.62%). This species was responsible for 57.14%
of the isolates from lab coats, 44.44% from hands of the
health care practitioners, and 35.29% from hospital depart-
ments. Our results contrast with other studies, which did
not identify C. glabrata as one of most isolated species in
Brazil.12,14 C. glabrata is considered a common commensal in
gastrointestinal and genitourinary tracts, but it can turn into
an opportunistic fungal pathogen in immunocompromised
patients.15
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Table 2 – Antifungal susceptibility proﬁle of Candida species isolated from the environment and staff of a Brazilian
Tertiary Hospital.
Candida species (number of isolates) Antifungal agent Classiﬁcation (% of isolates)
S SDD R
C. glabrata (8) Fluconazole 25.0 25.0 50.0
Amphotericin B 100.0 – –
Miconazole 25.0 62.5 12.5
Itraconazole 62.5 37.5 –
Ketoconazole 100.0 – –
Nystatin 100.0 – –
C. albicans (6) Fluconazole 66.6 33.3 –
Amphotericin B 100.0 – –
Miconazole 50.0 50.0 –
Itraconazole 33.3 66.6 –
Ketoconazole 100.0 – –
Nystatin 100.0 – –
C. parapsilosis (6) Fluconazole 83.3 16.7 –
Amphotericin B 100.0 – –
Miconazole 16.7 50.0 33.3
Itraconazole 16.7 50.0 33.3
Ketoconazole 100.0 – –
Nystatin 100.0 – –
C. tropicalis (6) Fluconazole 100.0 – –
Amphotericin B 100.0 – –
Miconazole 66.6 16.7 16.7
Itraconazole 16.7 50.0 33.3
Ketoconazole 83.3 16.7 –
Nystatin 100.0 –  –
C. krusei (4) Fluconazole – – 100.0
Amphotericin B 75.0 – 25.0
Miconazole – 50.0 50.0
Itraconazole – 75.0 25.0
Ketoconazole 100.0 – –
Nystatin 100.0 – –S, susceptible; SDD, dose-dependent susceptible; R, resistant.
C. parapsilosis and C. tropicalis were the next most com-
monly isolated species, responsible for 25.74% and 16.86% of
the isolates from all sources analyzed, respectively. Brazilian
reports have pointed these species as the main agents isolated
among non-albicans Candida species.14,16 In other countries
C. parapsilosis and C. tropicalis are also very frequent non-
albicans Candida species.13 C. tropicalis is an important fungal
pathogen in patients with neutropenia and/or with hemato-
logic malignancies.17 C. parapsilosis is known for ability to form
bioﬁlm on medical devices,18,19 for their persistence in the
nosocomial hospital environment, and for their propagation
by the hands.16
Environmental sources are more  commonly implicated
in infections caused by C. parapsilosis, when compared with
others Candida species20 and their importance has been high-
lighted in previous studies.6,21,22 According to our results, C.
krusei, C. lusitaniae and C. famata had the lowest rate of isola-
tion, as also reported in another study.23
Some cases of candidemia may be caused by clus-
ters of epidemiologically and genetically related strains
and therefore may be potentially preventable.23,24 Although
most candidemia cases occur due to a pre-existent colo-
nization in the patient, it may also be acquired throughmanipulation and direct contact made by the hands of health
care practitioners.25
The increased use of invasive medical procedures, as well
as the prophylactic and empirical use of antifungal drugs,
especially those of azolic derivation, has been responsible for
the emergence of non-albicans Candida species.26 The antifun-
gal susceptibility tests may be used in guiding treatment of
candidiasis, especially in situations where there is failure in
the initial empirical treatment.
In the present study, most of the isolates were susceptible
to ﬂuconazole. Resistant isolates of C. albicans were not found.
However, considerable levels of resistance were observed
among the isolates of non-albicans Candida. As expected, a high
resistance rate was observed in C. glabrata and C. krusei, which
are intrinsically less susceptible to this antifungal agent. This
proﬁle of susceptibility was also observed in Péman et al.27
Studies have shown that patients submitted to the pro-
phylactic ﬂuconazole are more  susceptible to colonization and
infection by C. glabrata because the exposure to subtherapeu-
tic concentrations of ﬂuconazole may result in resistance.8,28This species may present both innate and acquired resis-
tance against antifungal drugs, due to its ability to modify
ergosterol biosynthesis, mitochondrial function, or antifungal
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fﬂux. This resistance allows overgrowth in relation to suscep-
ible species and may contribute to the recent emergence of
nfections by C. glabrata in chronically immunocompromised
ndividuals.15
All C. krusei and C. glabrata isolates were susceptible to keto-
onazole and nistatin; most of them were also susceptible to
mphotericin B, with the exception of 25% of isolates of C. kru-
ei,  which presented resistance to this drug. These results are
onsistent with other studies.12,29
In our results, a resistance to the azoles Miconazole and
traconazole of up 33.3% in C. parapsilosis and C. tropicalis was
bserved (Table 2), while in the study of Bonﬁetti et al.30 all
he isolates of Candida spp. exhibited a high susceptibility to
traconazole. Our ﬁndings of susceptibility of C. tropicalis to ﬂu-
onazol are consistent with a previous Brazilian study which
eported susceptibility of all isolates of this species.22
Our data emphasize the importance of continuing surveil-
ance programs to evaluate the trends of Candida species,
ncluding critical species, like C. glabrata, and their resis-
ance proﬁles to antifungal drugs commonly used in medical
ractice. It is worth noting that voriconazole and caspofun-
in have been recently included as therapeutic choices in
he candidemia treatment. The resistance proﬁles for these
rugs must be continuously monitored, and the results must
e added to a national databank for empiric therapeutic
pproaches. Among the preventive measures, the active envi-
onmental surveillance and strict application of cleaning
rocedures should be implemented in order to prevent cross-
nfections and the onset of hospital outbreaks.
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